Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.
Vaccines (Basel)
; 11(2)2023 Feb 01.
Article
in En
| MEDLINE
| ID: mdl-36851204
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Journal:
Vaccines (Basel)
Year:
2023
Document type:
Article
Affiliation country:
RUSSIA
Country of publication:
Switzerland